The Role of Lactate Dehydrogenase in Exploring the Immune Evasion in HCC Patients Who Underwent TACE: Implications for Clinical Application
Yang Xie,Xiangyang Sun,Fubo Xie,Wencheng Jian,Qingliang Wang,Xiaochen Ma,Caixia Li,Kai Zhang
DOI: https://doi.org/10.2147/jhc.s480090
2024-09-29
Journal of Hepatocellular Carcinoma
Abstract:Yang Xie, Xiangyang Sun, Fubo Xie, Wencheng Jian, Qingliang Wang, Xiaochen Ma, Caixia Li, Kai Zhang Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China Correspondence: Kai Zhang, Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China, Tel +8618560081593, Email Purpose: To examine the relationship between lactate dehydrogenase (LDH) levels and soluble programmed cell death-ligand 1 (sPD-L1) levels in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Methods: A total of 83 hCC patients participated in this study. Patients were categorized into subgroups based on their alpha-fetoprotein (AFP) levels, presence or absence of extrahepatic metastasis, vascular invasion, Barcelona Clinic Liver Cancer (BCLC) stage, tumor response, tumor size, and number LDH and sPD-L1 levels were compared before and after TACE (3, 7, and 30 days post-TACE). Results: LDH and sPD-L1 levels were significantly higher at 3 and 7 days post-TACE than at baseline. Positive correlations were observed between changes in LDH levels and sPD-L1 levels at 3 and 7 days post-TACE. LDH levels were higher in patients with elevated AFP compared to those in the normal AFP group at 3 and 7 days post-TACE, in the stable disease (SD) group compared to complete response (CR) and partial response (PR) groups at 7 days post-TACE, and in those with tumor > 5 cm compared with those with tumor ≤ 5 cm at 3 and 7 days after TACE (all P 5 cm compared to those with tumor < 5 cm at 3 and 7 days after TACE (all P < 0.05). Conclusion: A positive correlation was found between LDH expression and sPD-L1 levels, suggesting LDH as a potential biomarker for assessing immune status in HCC patients following TACE. Keywords: hepatocellular carcinoma, immunotherapy, lactate dehydrogenase, soluble programmed cell death ligand-1, transarterial chemoembolization Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the third most common cause of cancer-related death globally. 1 Surgical resection is the primary treatment approach for individuals with early-stage HCC. However, owing to the subtle onset of HCC, the majority of patients receive diagnoses at intermediate or advanced stages, thereby missing the opportunity for radical treatment. 2 Moreover, almost 70% of HCC patients develop tumor recurrence within 5 years after surgery. 3 Consequently, non-radical treatments, including transarterial chemoembolization (TACE), chemotherapy, radiotherapy, multi-tyrosine kinase inhibitors (TKIs), and immunotherapy, assume pivotal roles in HCC management. Immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors, have garnered global approval for clinical use and are anticipated to enhance treatment outcomes in HCC. These agents can effectively counteract the immunosuppressive tumor microenvironment (TME) and reinstate the antitumor activity of the immune system by obstructing the interaction between checkpoint proteins and their ligands, thereby thwarting T cell inactivation. Recent endeavors have focused on augmenting the efficacy of ICIs by integrating them with locoregional therapies like TACE and ablation. 4,5 TACE is the most commonly employed treatment for unresectable HCC. However, the emergence of immune suppressive conditions post-TACE, 6,7 which tends to correlate with adverse prognoses, has also been suggested. 8 Consequently, administering ICIs after TACE to rectify the aberrant tumor immune environment appears logical. Nevertheless, HCC exhibits high heterogeneity with intricate biological and physiological features within the TME, and the immune status following TACE is complex and diverse. 9 The impact of ICIs on HCC may vary, with only a subset of patients benefitting from this treatment. 10 Hence, there is an urgent need to identify a dependable and readily detectable biomarker capable of delineating immune status within tumors post-TACE, which could aid in discerning patients who are responsive to ICIs. Lactate dehydrogenase (LDH) is a significant enzyme involved in carbohydrate metabolism. Elevated serum LDH levels are commonly observed in individuals with malignant tumors. Research indicates a close association between LDH and various tumor-related biological processes, including drug resistance, angiogenesis, and metastasis.<su -Abstract Truncated-
oncology